Silence Therapeutics Funding News – Silence Therapeutics Raises $2 Million

Read also - CarCloud funding news – Car Finance Platform CarCloud Secures £425k in Seedrs Round Funding

Hansoh made a $16 million upfront payment to Silence and the Company is eligible to receive up to $1.3 billion in development, regulatory and commercial milestones. Silence Therapeutics is also eligible to receive royalties tiered from low double-digit to mid-teens on Hansoh net product sales. Today’s announcement represents the fourth research milestone payment achieved under the collaboration.

Read also - Net Zero Company funding news – Carbon Removal Company Net Zero Company Secures $5.5 Million in Seed Funding

“This represents an important milestone in our efforts to advance this program into the clinic with Hansoh,” said Craig Tooman, President and CEO of Silence. “This is an exciting time for Silence and our mRNAi GOLD™ platform as we continue to advance and expand our pipeline targeting a wide range of genetic diseases.”

Silence and Hansoh entered a collaboration in October 2021 to develop siRNAs (“short interfering RNAs”) leveraging Silence’s proprietary mRNAi GOLD™ platform for three undisclosed targets. Under the terms of the agreement, Silence has exclusive rights to the first two targets in all territories except the China region. Hansoh has the exclusive option to license rights to those two targets in the Greater China, Hong Kong, Macau and Taiwan, and global rights to the third target.

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity.